FDA inspected NuGeneration Technologies' Emeryville, California drug plant and found CGMP failures in hand sanitizer release testing, ingredient and water testing, stability and process validation.
What happened
FDA inspected NuGeneration Technologies' drug manufacturing facility at 1155 Park Avenue in Emeryville, California from September 14 to September 22, 2022. Investigators found the company released its NuRinse Hand Sanitizer without full release testing, did not test incoming ethanol and deionized water, lacked stability data for expiration dates, and had not validated its manufacturing process. FDA reviewed the company's October 12, 2022 response to the Form FDA 483 (the list of observations given at the end of an inspection) and called it inadequate.
What FDA found
The company released hand sanitizer batches without testing them for identity and strength of the active ingredient or for impurities and microbes.
21 CFR 211.165(a)The company relied on certificates of analysis from unqualified ethanol suppliers and did not test each incoming lot of ethanol itself for identity.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not test incoming ethanol for methanol, which has caused fatal poisonings worldwide.
21 CFR 211.84(d)(2)The company could not show its deionized water system consistently makes water meeting the USP Purified Water standard, and it did not properly test for total organic carbon, microbes, or record conductivity.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company had no stability data to support the expiration dates of hand sanitizer already in distribution.
21 CFR 211.166(a)The company had not validated the manufacturing process for its hand sanitizer.
21 CFR 211.100(a)
What FDA wants
FDA tells the company to correct the violations promptly and to reply in writing within 15 working days describing what it has done and how it will prevent recurrence; if more time is needed, it must explain the delay and give a schedule. FDA also strongly recommends hiring a qualified CGMP consultant.
Who should pay attention
- distributors and retailers selling NuRinse hand sanitizer
- contract manufacturers of alcohol-based hand sanitizers
- companies that rely on supplier certificates of analysis instead of testing incoming ingredients
This is a summary. Read the original letter on fda.gov.